Abstract
INTRODUCTION
Biomarkers for Alzheimer’s disease (AD) are now available for clinical use; however, little is known about their use in primary care.
METHODS
Cross-sectional analysis of 2024 data from the National Dementia Workforce Study, a nationally representative survey of primary care providers (PCPs) who treat Medicare beneficiaries with dementia. We used survey weights to generate nationally representative estimates of self-reported biomarker use.
RESULTS
Among 2574 PCPs, computed tomography/magnetic resonance imaging (CT/MRI) (79%) and neuropsychological testing (71%) were most commonly used, followed by positron emission tomography (PET) (18%), plasma (16%), genetic (14%), and CSF testing (9%). PCPs confident in diagnosing dementia and from specialist settings were more likely to report ordering PET, plasma, genetic, and CSF testing.
DISCUSSION
This study describes patterns in the adoption of AD biomarkers in the year after Medicare expanded coverage for some biomarkers, providing a baseline for measuring changes in biomarker use. Guidelines are needed to inform PCP decision-making for biomarkers.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: | July 12, 2026
Neuro-Dementia